Harbin Gloria Pharma and WuXi Biologics have entered an ex-China agreement for a PD-1 antibody with Arcus Biosciences of California’s Bay Area in a deal worth up to $818 million. The PD-1 candidate, GLS-010, is currently in a China Phase I trial. Arcus will pay $18.5 million upfront for rights to GLS-010 in North America, Europe, Japan and other unspecified territories. It will also be liable for $422.5 million in development and regulatory milestones on combinations of GLS-010 and 11 Arcus products. Commercial milestones will add another $375 million to the agreement, and Arcus will also pay royalties on sales.
Source: ChinaBio Today
